Nutriband Inc
$ 4.43
2.07%
24 Feb - close price
- Market Cap 53,935,000 USD
- Current Price $ 4.43
- High / Low $ 4.43 / 4.25
- Stock P/E N/A
- Book Value 0.62
- EPS -3.05
- Next Earning Report 2026-05-01
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.55 %
- ROE -1.36 %
- 52 Week High 11.68
- 52 Week Low 3.96
About
Nutriband Inc. develops a portfolio of transdermal pharmaceuticals. The company is headquartered in Orlando, Florida.
Analyst Target Price
$15.00
Next Quarterly Earnings
| Apr 2026 | |
|---|---|
| Reported Date | 2026-05-01 |
| Fiscal Date Ending | 2026-04-30 |
| Estimated EPS | -1.89 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: NTRB
2026-02-17 20:27:32
Nutriband (NASDAQ: NTRB) has secured an exclusive distribution agreement with Innomedica in Costa Rica for its AVERSA Fentanyl product, pending approval, and its sports tape products. Innomedica will manage regulatory approvals and funding for the launch. Nutriband's AVERSA technology aims to prevent abuse and misuse of fentanyl patches by incorporating aversive agents.
2026-02-17 12:27:54
Nutriband Inc. has signed an exclusive distribution agreement with Costa Rica-based Innomedica for its AVERSA Fentanyl product, upon approval, and all sports tape products. Innomedica will also manage and finance the regulatory approvals for these products in Costa Rica. The AVERSA technology is designed to prevent the abuse, diversion, misuse, and accidental exposure of drugs with abuse potential by incorporating aversive agents into transdermal patches.
2026-02-17 07:28:00
Nutriband Inc. has signed an exclusive distribution agreement with Costa Rica-based Innomedica for its AVERSA Fentanyl product, pending approval, and all sports tape products manufactured by its subsidiary. Innomedica will also manage and finance the regulatory approval processes for these products in Costa Rica. Nutriband's AVERSA™ technology is designed to deter the abuse, diversion, misuse, and accidental exposure of drugs with abuse potential in transdermal patches.
2026-02-14 00:28:00
Nutriband has terminated the planned sale of its subsidiary, Pocono Pharmaceuticals, Inc., to Earth Vision Bio Inc. The cancellation resulted from the buyer's failure to pay required late fees after missing the December 31, 2025 closing date. This decision means Pocono Pharmaceuticals will remain under Nutriband’s control, impacting its portfolio strategy.
2026-02-13 22:28:00
NutriBand Inc. announced the termination of its subsidiary sale agreement with Earth Vision Bio Inc. on February 13, 2026. This termination was due to the purchaser's failure to pay late fees, though NutriBand did receive $30,000 in late fees prior to the agreement's cancellation. The event was detailed in an 8-K SEC filing.
2026-02-13 22:28:00
Nutriband Inc.'s board of directors has officially terminated its agreement to sell a subsidiary to Earth Vision Bio, as per an SEC filing. The termination was due to Earth Vision Bio's failure to pay agreed-upon late fees, invalidating the previous transaction. The company did not disclose further details regarding the specific fees or future handling plans.
